Form 8-K bluebird bio, Inc. For: Nov 03
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Goldman Sachs Downgrades bluebird bio (BLUE) to Sell
November 8, 2021 7:38 AM ESTGoldman Sachs analyst Salveen Richter downgraded bluebird bio (NASDAQ: BLUE) from Neutral to Sell with a price target of $10.00 (from $23.00).
The analyst comments "We downgrade BLUE to Sell from Neutral and lower our 12-month PT to $10 from $23. Post the separation of the severe genetic disease (SGD; BLUE) and oncology businesses (2seventy bio; TSVT), BLUE is focused on developing and... More
Morgan Stanley Downgrades bluebird bio (BLUE) to Underweight, 'commercialization will remain challenging'
November 8, 2021 5:11 AM ESTMorgan Stanley analyst Matthew Harrison downgraded bluebird bio (NASDAQ: BLUE) from Equalweight to Underweight with a price target of $11.00 (from $19.00).
The analyst comments "Bluebird has developed a robust portfolio of genetherapies where we expect approval in 2022/2023. However, we believe the ultimate market for... More
